Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Extended release niacin Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

NCT00986986
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Endothelial Dysfunction
Interventions
extended release niacin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 4 Interventional

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

NCT00345657
View directory record Official record
Conditions
Hyperlipidemia, Mixed Hyperlipidemia, Dyslipidemia
Interventions
Niacin Extended Release/Lovastatin
Drug
Lead sponsor
In His Image
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 27, 2006 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
View directory record Official record
Conditions
Healthy
Interventions
atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 2, 2026, 4:02 PM EDT
Terminated Not applicable Interventional Results available

Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid

NCT01159054
View directory record Official record
Conditions
Dialysis, Cardiovascular Disease, Atherosclerosis, Inflammation
Interventions
Extended Release Nicotinic Acid (Niaspan)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

NCT00630877
View directory record Official record
Conditions
Dyslipidemia
Interventions
Niacin extended-release (NER), Niacin extended-release (NER) placebo, Aspirin (ASA), Aspirin (ASA) placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Walnut Creek, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Sep 2, 2026, 4:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Nicotinic Acid for the Treatment of Alzheimer's Disease

NCT06582706
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo Comparator, Extended Release Niacin
Drug
Lead sponsor
Indiana University
Other
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

NCT00626392
View directory record Official record
Conditions
Dyslipidemia
Interventions
niacin extended-release (NER), aspirin (ASA), aspirin placebo (ASA Pbo)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 2, 2026, 4:02 PM EDT
Completed No phase listed Observational

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

NCT01178320
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Simvastatin, simvastatin plus extended-release niacin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
15
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Effects of Niacin Therapy on Lipoprotein Composition and Function

NCT02322203
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Niacin Extended Release
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
View directory record Official record
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment
Drug
Lead sponsor
University of South Dakota
Other
Eligibility
40 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

Effects of Niacin On Fatty Acid Trapping

NCT01984073
View directory record Official record
Conditions
Dyslipidemia
Interventions
ER Niacin Oral Fat Challenge, IR Niacin Oral Fat Challenge, Placebo Oral Fat Challenge
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis

NCT01221402
View directory record Official record
Conditions
Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis, Intermediate Saphenous Vein Graft Lesions
Interventions
extended-release niacin (Niaspan)
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

NCT00071266
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease
Interventions
Niacin Extended Release and Lovastatin Tablets
Drug
Lead sponsor
Kos Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Sep 2, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 2, 2026, 4:02 PM EDT
Terminated Phase 4 Interventional

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

NCT00397657
View directory record Official record
Conditions
Atherosclerosis
Interventions
extended release niacin, ezetimibe
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Takoma Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2009 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study

NCT00953667
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Immediate Release Niacin, Extended Release Niacin, Endotoxin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 2, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

NCT00046267
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Diabetes Mellitus
Interventions
Niacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 2, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional Results available

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

NCT02702492
View directory record Official record
Conditions
Solid Tumors, NHL
Interventions
KPT-9274, Niacin ER, Nivolumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 2, 2026, 4:02 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Pathways of Eicosanoid Metabolism

NCT04464070
View directory record Official record
Conditions
Metabolism of Prostaglandin D2
Interventions
niacin, aspirin, PGD2
Dietary Supplement · Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 2, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery

NCT00796887
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Extended-Release Niacin, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 2, 2026, 4:02 PM EDT